Fig. 2.

Pro-tumoral role of IL-17 during the early phase of MM. a M-spike incidence over time (weeks) in cohorts of Vk*MYC mice either competent (Vk*MYC IL-17^WT) or deficient for IL-17 (Vk*MYC IL-17^KO) and WT littermates. Unpaired t test: *P < 0.05. b Incidence of M-spike ≥ 6%, corresponding to symptomatic, Late-MM³³, in the mice depicted in a. Unpaired t test: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. c, d Absolute numbers (c) and frequency (d) of IL-17⁺ cells in the BM of Vk*MYC mice and age-and sex-matched WT littermates. Each dot is representative of an individual mouse. Mean ± SD of five independent experiments. Unpaired t test: *P < 0.05; **P < 0.01; ***P < 0.001. e Ratio between Th17 cells and malignant plasma cells (IRF4/MUM1⁺). Mean ± SD of five independent experiments. Whitney test: *P < 0.0159. c–e Specific n values of biologically independent mice are shown